<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Homeodomain-only protein X (HOPX)-β promoter methylation was recently shown to be frequent in human <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancers</z:e> and was suggested as <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> suppressor gene in esophageal and <z:hpo ids='HP_0012126'>gastric cancer</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>The aim of this study was to investigate the mechanistic roles of HOPX-β promoter methylation and its clinical relevance in <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e>) </plain></SENT>
<SENT sid="2" pm="."><plain>HOPX-β promoter methylation was assessed in human <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> cell lines and 294 CRC tissues </plain></SENT>
<SENT sid="3" pm="."><plain>HOPX <z:chebi fb="2" ids="33699">mRNA</z:chebi> and protein levels were measured in relation to HOPX-β promoter methylation </plain></SENT>
<SENT sid="4" pm="."><plain>The effects of forced HOPX expression on <z:mp ids='MP_0002006'>tumorigenesis</z:mp> were studied using in vitro and in vivo assays </plain></SENT>
<SENT sid="5" pm="."><plain>The association between HOPX-β promoter methylation and clinical relevance of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> patients was determined </plain></SENT>
<SENT sid="6" pm="."><plain>HOPX-β promoter methylation is <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e>-specific and frequently found in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> cell lines and tissues, resulting in the down-regulation of HOPX <z:chebi fb="2" ids="33699">mRNA</z:chebi> and protein levels </plain></SENT>
<SENT sid="7" pm="."><plain>In <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> cell lines, forced expression of HOPX suppressed proliferation, invasion, and anchorage-independent growth </plain></SENT>
<SENT sid="8" pm="."><plain>DNA microarray analyses suggested critical downstream genes that are associated with <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> cell proliferation, invasion or <z:mpath ids='MPATH_177'>angiogenesis</z:mpath> </plain></SENT>
<SENT sid="9" pm="."><plain>In a mouse <z:e sem="disease" ids="C1520166" disease_type="Experimental Model of Disease" abbrv="">xenograft model</z:e>, HOPX inhibited <z:mp ids='MP_0002006'>tumorigenesis</z:mp> and <z:mpath ids='MPATH_177'>angiogenesis</z:mpath> </plain></SENT>
<SENT sid="10" pm="."><plain>Finally, HOPX-β promoter methylation was associated with worse prognosis of stage III <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> patients (hazard ratio= 1.40, P = .035) and also with poor differentiation (P = .014) </plain></SENT>
<SENT sid="11" pm="."><plain>In conclusion, HOPX-β promoter methylation is a frequent and <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e>-specific event in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> progression </plain></SENT>
<SENT sid="12" pm="."><plain>This epigenetic alteration may have clinical ramifications in the diagnosis and treatment of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> patients </plain></SENT>
</text></document>